Hyalex Orthopaedics

What Hyalex Orthopaedics does

Hyalex Orthopaedics is a privately held, clinical-stage medical device company founded in 2016 and headquartered in Lexington, Massachusetts. The company is developing the HYALEX® Cartilage System, a biomimetic synthetic cartilage implant designed to replicate the structure and function of native hyaline cartilage. The core technology is the HYDROSURF Materials Platform — a proprietary composition combining a strength component and a water-attracting component — bonded to medical-grade porous titanium to deliver a single-step, off-the-shelf solution for cartilage defect repair. Hyalex's lead clinical product is the HYALEX Freestyle Knee Implant, intended for patients with loss of knee articular cartilage in the "treatment gap" between biologic therapies and total joint replacement.

Name

Hyalex Orthopaedics

Legal name

Hyalex Orthopaedics, Inc.

Website

https://hyalex.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Hyalex Orthopaedics is a privately held, clinical-stage medical device company developing the proprietary HYALEX® synthetic cartilage platform for single-step, off-the-shelf repair of knee cartilage lesions in patients underserved by existing therapies.

Ownership category

akta.pro rank

Product category

Orthopaedic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industry

Hip & Knee Reconstruction (Arthroplasty) (HLAKALAH)

Keywords

• Synthetic cartilage implants
• Orthopaedic medical devices
• Knee cartilage repair
• Biomimetic biomaterials
• Joint preservation technology

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales (Future): Hyalex is a pre-revenue medical device company in clinical stage. Upon FDA approval and commercialization, the company will generate revenue through the sale of HYALEX Knee Cartilage System implants and instrumentation to hospitals and surgical centers.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Hyalex Orthopaedics develops and is preparing to commercialize the HYALEX Cartilage System, a proprietary biomimetic synthetic cartilage material designed to replicate the structure and function of native hyaline cartilage for orthopaedic joint repair. The company's lead product is the HYALEX Knee System, which combines the synthetic cartilage material with medical-grade porous titanium for single-step surgical treatment of knee cartilage lesions, addressing the treatment gap between biologic therapies and total joint replacement.

Product overview

Hyalex Orthopaedics offers a synthetic cartilage platform built on the HYDROSURF Materials Platform. The core product line includes the HYALEX Cartilage System—a biomimetic material engineered to replicate native cartilage—and the HYALEX Knee System, which incorporates this technology into a complete surgical solution. The HYALEX Freestyle Knee Implant represents the company's latest implant iteration for patients with cartilage damage and early osteoarthritis. All implants feature proprietary HYALEX Cartilage material bonded to medical-grade porous titanium, designed for single-step, off-the-shelf deployment.

Differentiator

Problem solved

Functional benefit

Brands

• HYALEX Cartilage System: Biomimetic synthetic cartilage implant for knee cartilage repair
• HYALEX Knee System
• HYALEX Freestyle Knee Implant
• HYALEX HYDROSURF Materials Platform

Products and services

• HYALEX Cartilage System A biomimetic synthetic cartilage platform engineered to replicate the structure and function of hyaline cartilage. The material combines a strength component and a water-attracting component to match native cartilage properties, providing high strength, low friction, and low wear for cartilage repair.
• HYALEX Knee System A comprehensive knee cartilage repair system designed to address the treatment gap for cartilage defects found in approximately 60% of knee arthroscopies. The system includes proprietary synthetic HYALEX Cartilage material bonded to medical-grade porous titanium and aims to restore knee joint surface in a single surgical treatment.
• HYALEX Freestyle Knee Implant A cutting-edge knee implant designed to enable patients suffering from cartilage damage and early osteoarthritis of the femoral condyle(s) to regain an active lifestyle. The implant has expanded from Early Feasibility Study (EFS) to pivotal clinical trial following FDA IDE supplement approval.

Quantifiable outcome

• Approximately 750,000 cartilage injuries diagnosed annually in the US represent potential addressable market
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• MedTech InnovatorminorGTM or Marketing Partner · 20 June 2020Hyalex was honored to be in the MedTech Innovator 2020 Showcase Company cohort, gaining visibility and networking opportunities within the medical device ecosystem.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Vericel Corporation: Vericel commercializes MACI, the leading FDA-approved autologous chondrocyte implant for knee cartilage repair. It is the most direct competitor to Hyalex's HYALEX Cartilage System in cartilage lesion treatment.
• Anika Therapeutics: Specialty orthopedic company developing hyaluronic acid-based cartilage preservation therapies and joint pain treatments. Closely comparable therapeutic focus to Hyalex's biomimetic cartilage approach.
• Bioventus: Orthobiologics company with cartilage repair and joint preservation products (e.g., bone marrow aspirate, allograft cartilage solutions). Directly competes with Hyalex in the joint preservation/cartilage repair market.
• Joint Restoration Foundation (JRF) Ortho: Non-profit provider of allograft cartilage and osteochondral grafts used in cartilage repair procedures. Represents the current allograft-based approach that Hyalex aims to replace with its off-the-shelf synthetic alternative.

Broad incumbents

• Smith & Nephew: Global orthopedic and sports medicine leader with cartilage repair offerings (including the acquired CartiHeal Agili-C implant) and a full knee replacement portfolio. Overlaps with Hyalex in cartilage repair and competes for the same sports medicine surgeon relationships.
• Zimmer Biomet: One of the largest orthopedic device companies globally, with extensive knee replacement and sports medicine franchises. Several Hyalex executives (CTO Mike Hawkins, Director Craig Fryman) previously held senior roles at Zimmer, reflecting the deep technical and commercial overlap.
• Stryker: Major orthopedic and sports medicine incumbent with strong knee and cartilage-related product lines. Competes for the same hospitals, surgeons, and 'treatment gap' patients that Hyalex targets.
• Arthrex: Private sports medicine leader with a broad portfolio of cartilage repair and joint preservation products, including autologous cartilage implantation tools. Targets the same orthopedic surgeons and patient population as Hyalex.
• CONMED Corporation: Orthopedic and sports medicine device manufacturer with a broad sports medicine portfolio. Hyalex CEO Carl Vause previously led CONMED's orthopedic solutions business, and CONMED's sports medicine line competes for similar surgeons.

Emerging players

• ConforMIS: Develops patient-specific (custom) knee replacement implants using 3D printing. Competes for the same 'treatment gap' patient population but addresses them via customized arthroplasty rather than cartilage replacement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hyalex-orthopaedics-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyalex Orthopaedics